Scarica l'app Stockscreener
7.70
2.53%
-0.20
Dopo l'orario di chiusura:
7.80
0.10
+1.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
Discontinued operations of Verastem, Inc. – HAN:2VSA - TradingView
Verastem, Inc. Actuals & Estimates (HAN:2VSA) - TradingView
Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance Australia
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Verastem (VSTM) Shares React to Positive Two-Year Phase 2 RAMP 201 Study Results in Ovarian Cancer - GuruFocus
Half of patients with a specific ovarian cancer mutation stayed on treatment for over a year. - Stock Titan
Cantor Fitzgerald reiterates Overweight on Verastem stock ahead of data By Investing.com - Investing.com Nigeria
Understanding the Setup: (VSTM) and Scalable Risk - Stock Traders Daily
Verastem to present cancer treatment study data at IGCS meeting - Investing.com
Verastem to present cancer treatment study data at IGCS meeting By Investing.com - Investing.com Canada
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting - Business Wire
Form 4 Verastem Inc For: 23 September By Investing.com - Investing.com Canada
Form 4 Verastem Inc For: 23 September - Investing.com India
Verastem CFO Daniel Calkins sells $423 in company stock - Investing.com
Verastem CFO Daniel Calkins sells $423 in company stock By Investing.com - Investing.com South Africa
Verastem (VSTM) CFO Daniel Calkins Sells 55 Shares, Insider Owne - GuruFocus
After selling 55 shares, Verastem (VSTM) CFO Daniel Calkins directly owned 118,014 shares. - Stock Titan
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright - TradingView
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Verastem Inc. Share PriceVSTM, RNS News, Articles, Quotes, & Charts (NASDAQ:VSTM) - Proactive financial news
RBC Capital Keeps Their Buy Rating on Verastem (VSTM) - The Globe and Mail
Verastem Stock Price Forecast. Should You Buy VSTM? - StockInvest.us
Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says - marketscreener.com
Verastem, Inc. (VSTM) Stock Analysis: Unveiling a 94% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $14 - Moomoo
Verastem Repeat Insider Selling Not A Positive Indicator - Moomoo
Wolfe Research Initiates Verastem at Outperform - Yahoo Finance
Wolfe Research Maintains Verastem(VSTM.US) With Buy Rating - Moomoo
(VSTM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
H.C. Wainwright reiterates Verastem stock rating on cancer trial data By Investing.com - Investing.com Canada
Verastem Oncology at H.C. Wainwright: dual-track RAS push By Investing.com - Investing.com Canada
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - The Globe and Mail
Verastem (VSTM) Plans Investor Event to Reveal Preliminary Data on VS-7375 Amid Mixed Market Signals - GuruFocus
A cancer drug’s first broad safety update is set for Oct. 14 from Verastem - Stock Titan
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers - Business Wire
VSTM 8-K FilingsVerastem, Inc. SEC 8-K - Stock Titan
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Yahoo! Finance Canada
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):